Skip to main content
Fig. 4 | Diabetology & Metabolic Syndrome

Fig. 4

From: The safety of SGLT-2 inhibitors in diabetic patients submitted to elective percutaneous coronary intervention regarding kidney function: SAFE-PCI pilot study

Fig. 4

Creatinine levels at pre-specified time-points. There was no difference in baseline creatinine levels (p = 0.061) between groups. In the SGLT2i group, an absolute increase in creatinine from baseline to creatinine levels at pre-PCI and 24 h after PCI was observed when compared to the Control group. However, the difference between groups after 48 h of PCI was not statistically significant. *Test-t used to compare two creatinine levels in different groups. **One-way ANOVA with repeated measures was used to compare creatinine levels in different times in each group

Back to article page